Literature DB >> 11168511

Diabetes insipidus revealing acute myelogenous leukaemia with a high platelet count, monosomy 7 and abnormalities of chromosome 3: a new entity?

T Lavabre-Bertrand1, P Bourquard, J Chiesa, M F Berthéas, G Lefort, J Taïb, C Lavabre-Bertrand, M Navarro, J P Bureau.   

Abstract

We describe three cases of acute myeloid leukaemia revealed by diabetes insipidus. The patients were 42, 38 and 39 yr old and they had marked hyperleukocytosis, circulating immature granular cells and a normal or elevated platelet count. The leukaemia was type AML-M2 according to the FAB classification. Cytogenetic studies showed inversion of chromosome 3 (q21;q26) in 2 cases and a translocation (3;3)(q21;q29?) in the remaining case, both associated with monosomy 7. All the cerebral CT scans were normal. Complete remission was never achieved, and all three patients survived less than 14 months. Desmopressin therapy was active but treatment could not be reduced. The association of dysmegakaryopoiesis with a chromosome 3 abnormality and diabetes insipidus is probably not fortuitous and could represent a new entity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168511     DOI: 10.1034/j.1600-0609.2001.00346.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

1.  Can a high platelet count be responsible for diabetes insipidus in acute myelogenous leukemia with monosomy 7 and inversion 3 (q21q26)?

Authors:  Mehmet Sonmez; Nergiz Erkut; T Songul Tat; Figen Celep; Umit Cobanoglu; H Onder Ersoz
Journal:  Int J Hematol       Date:  2009-08-12       Impact factor: 2.490

2.  Acute myeloid leukemia with monosomy 7, ectopic virus integration site-1 overexpression and central diabetes insipidus: A case report.

Authors:  Hongbing Ma; Jing Yang; Bing Xiang; Yongqian Jia
Journal:  Oncol Lett       Date:  2015-04-23       Impact factor: 2.967

3.  Acute myeloid leukemia with 3q26 abnormality: An editorial perspective.

Authors:  K Ghosh
Journal:  J Postgrad Med       Date:  2018 Apr-Jun       Impact factor: 1.476

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.